A recent study suggests that medications commonly used to treat symptoms of an enlarged prostate may also lower the risk of developing dementia with Lewy bodies (DLB). DLB is a type of dementia that causes memory, thinking, and movement issues, as well as confusion and hallucinations.
The research found that men who took certain drugs like terazosin, doxazosin, and alfuzosin were 40% less likely to develop DLB compared to those taking other prostate medications. These drugs belong to a class known as alpha blockers, which help relax the muscles of the bladder and prostate to ease urinary symptoms.
The study, conducted by researchers at the University of Iowa, analyzed health records of over 643,000 men without a history of DLB who were taking various prostate drugs. The results showed that those taking terazosin, doxazosin, or alfuzosin had lower rates of DLB compared to those on different medications like tamsulosin and 5ARIs.
Although the findings are promising, more research is needed to establish a cause-and-effect relationship between these medications and the prevention of DLB. It is essential to conduct further clinical trials to confirm the potential protective effect of these drugs on this form of dementia.
Dr. Julia Dudley from Alzheimer’s Research UK emphasized the importance of exploring existing drugs’ potential to protect against dementia. She highlighted the need for future studies to include a more diverse group of participants, as the current research only focused on male individuals, despite women also using similar medications for urinary symptoms.
In conclusion, the study opens up possibilities for using already approved drugs to combat neurodegenerative diseases like DLB. While these findings are encouraging, additional research and clinical trials are necessary to validate the effectiveness of these medications in preventing or slowing down the progression of dementia with Lewy bodies. Expanding the scope of future studies to include a broader range of participants will be crucial in understanding the full potential of these drugs in treating such conditions.
